The long-awaited emergency use authorization (EUA) for Novavax’s (NVAX) Covid-19 vaccine NVX-CoV2373 was finally granted last month, bringing to an end a journey that began early in the pandemic. For
The long-awaited emergency use authorization (EUA) for Novavax’s (NVAX) Covid-19 vaccine NVX-CoV2373 was finally granted last month, bringing to an end a journey that began early in the pandemic. For
Competition for top dog billing in the Covid-19 vaccine space has basically turned into a two-horse race. So far, Pfizer (PFE)/BioNTech (BNTX) lead the way, but Moderna (MRNA) has provided
Rising Covid-19 cases in China have sent Shenzhen and other cities back into lockdown and there have also been newly confirmed cases in other countries/regions such as the UK, Australia
After several delays and setbacks, Novavax (NVAX) finally filed an EUA request for its Covid-19 vaccine with the FDA at the end of January. Given precedents and the company’s recent
Vaxart (VXRT) shot to prominence in the early days of the pandemic, as one of the small vaccine makers taking the fight to Covid-19. But that was a while ago